Background and purpose: Next-generation sequencing has greatly improved the diagnostic success rates for genetic neuromuscular disorders (NMDs). Nevertheless, most patients still remain undiagnosed, and there is a need to maximize the diagnostic yield. Methods: A retrospective study was conducted on 72 patients with NMDs who underwent exome sequencing (ES), partly followed by genotype-guided diagnostic reassessment and secondary investigations. The diagnostic yields that would have been achieved by appropriately chosen narrow and comprehensive gene panels were also analysed. Results: The initial diagnostic yield of ES was 30.6% (n = 22/72 patients). In an additional 15.3% of patients (n = 11/72) ES results were of unknown clinical significance. After genotype-guided diagnostic reassessment and complementary investigations, the yield was increased to 37.5% (n = 27/72). Compared to ES, targeted gene panels (<25 kilobases) reached a diagnostic yield of 22.2% (n = 16/72), whereas comprehensive gene panels achieved 34.7% (n = 25/72). Conclusion: Exome sequencing allows the detection of pathogenic variants missed by (narrowly) targeted gene panel approaches. Diagnostic reassessment after genetic testing further enhances the diagnostic outcomes for NMDs.
Introduction
Neuromuscular disorders (NMDs) represent a clinically and genetically heterogeneous group of diseases affecting motor neurons, peripheral nerves, the neuromuscular junction or muscle tissue, often with an overlapping range of symptoms. A considerable proportion of NMDs are known or suspected to have a monogenic aetiology. However, due to the marked phenotypic overlap and the contribution of as yet unidentified disease genes, single gene testing has been widely unsuccessful.
With the advent of next-generation sequencing (NGS) approaches such as gene panels, exome sequencing (ES) or genome sequencing, a growing number of causative variants can be identified [1] [2] [3] . Even so, the majority of patients with NMDs still remain undiagnosed with variable success rates, mainly depending on the selected patient population and the applied method [4] [5] [6] [7] [8] [9] [10] [11] [12] . It is therefore a major challenge facing clinicians and geneticists to further enhance the application of NGS techniques.
For example, it is a subject of ongoing debate which exact NGS approach is optimal from a diagnostic and cost-point perspective [13] . ES has the inherent potential to identify novel disease genes and allows a diagnostic re-evaluation at a later time, whereas gene panels are postulated to secure a higher coverage. The diagnostic utility of comprehensive panels and ES has been considered to be comparable in practice [14, 15] . In contrast, it is still unclear whether the widely used small-scale panelsas often mandated by national health care providersachieve similar results.
Another issue requiring refinement is the correct identification of causative variants against the abundance of irrelevant background variation. The widely used guidelines of the American College of Medical Genetics and Genomics (ACMG) consider various strands of genetic and clinical evidence for variant classification [16] . Whilst some variants can reliably be classified as benign or pathogenic right away, the causative effect often remains uncertain after genetic testing (variants of unknown significance, VUS) [17] . It has already been shown that uncertain findings can be successfully reclassified using clinical reconsideration, complementary family genotyping or supporting functional data [18] [19] [20] . Such approaches have the ability to reveal minor and initially overlooked clinical features, bringing to light specific phenotypic fits potentially underpinning the pathogenic relevance of variants.
In this retrospective analysis of routine ES in patients with NMDs, an evaluation was made of the degree to which a critical reassessment after ES may enhance the diagnostic outcomes in a real-world setting. Secondly, diagnostic ES was virtually compared to frequently used NGS gene panels.
Methods

Patients
All patients with neuromuscular phenotypes seen at the Department of Neurology (Medical University of Vienna, Austria) who underwent diagnostic ES between July 2015 and December 2018 were retrospectively selected. The indication was determined after reviewing and complementing prior diagnostic procedures. A genetic aetiology was considered by NMD specialists, if no acquired cause could be established after an extensive diagnostic work-up.
Informed consent (also regarding actionable findings) was obtained from included patients. The study was approved by the Ethics Committee of the Medical University of Vienna.
Exome sequencing and data analysis
Exomes were enriched in solution with SureSelect Human All Exon Kits 50 Mb V5 and 60 Mb V6 (Agilent, Santa Clara, CA, USA). DNA fragments were sequenced as 100 bp paired-end runs on an Illumina HiSeq2500 or HiSeq4000 system (Illumina, San Diego, CA, USA). The mean average coverage in our exome dataset was 146.89.
Variants were filtered based on the minor allele frequency (MAF), which was estimated using our in-house database (>15 000 exomes) and confirmed by ExAC, (https://exac.broadinstitute.org) or gnomAD, (https:// gnomAD.broadinstitute.org). Variant prioritization was based on autosomal recessive (MAF < 0.1%) and autosomal dominant (MAF < 0.01%) filters. Copy number variation analysis was done using ExomeDepth [21] and Pindel [22] . A detailed description of the sequencing and data analysis pipeline is provided as supplementary file (Data S1).
Variant interpretation by genetic laboratory
Using ACMG criteria, variants were classified as (i) pathogenic, (ii) likely pathogenic or (iii) VUS [16] . VUS that were not related to the phenotype in question and (likely) benign variants were not reported. (Likely) pathogenic variants were considered sufficient for establishing a genetic diagnosis for dominant disorders. For recessive disorders, two (likely) pathogenic variants were required. Otherwise, for example in the case of one pathogenic variant and one VUS, the laboratory conclusion was considered of 'unknown clinical significance'. Exomes were screened for actionable variants as recommended by ACMG [23] . At the time of initial analysis, basic clinical information was available for geneticists.
Diagnostic reassessment and variant reclassification
After ES, all (likely) pathogenic variants were considered causative, if compatible with the inheritance pattern and phenotype (definite/likely diagnoses). VUS in genes related to the NMD phenotype guided diagnostic reassessment with the aim of clarifying their clinical relevance. Investigations such as family genotyping, histology or biochemical analyses were initiated. Existing literature on previously reported families with mutations in the same gene was specifically screened to compare the phenotypes with our index cases. After reassessment, VUS were re-evaluated and partly reclassified according to ACMG [16] . Since ACMG only provides categories for variants, the following categories were additionally defined to provide patients with a firm diagnostic conclusion (as suggested by Shashi et al. [19] ): (i) definite diagnosis (one pathogenic variant for dominant and two pathogenic variants for recessive disorders), (ii) probable diagnosis (one likely pathogenic variant for dominant and at least two likely pathogenic variants for recessive disorders), (iii) possible diagnosis (one VUS for dominant and either one VUS and one (likely) pathogenic variant or two VUS for recessive disorders) and (iv) no diagnosis. Final decisions were made after an interdisciplinary discussion involving NMD specialists and a geneticist.
Comparison of exome sequencing to gene panels
To virtually compare the diagnostic yields between gene panels and ES, one commercially available targeted panel comprising less than 25 kilobases (kb) that seemed most appropriate for each individual phenotype (4-17 genes) and one comprehensive NGS panel (up to 344 genes) were retrospectively selected. The diagnostic yields of both selected panels were compared to the outcome of ES (Table S1 ).
Results
Patient characteristics
In all, 72 patients with neuromuscular phenotypes underwent diagnostic ES between July 2015 and December 2018 and were selected for analysis.
The median age at the time of ES was 47 years (range 19-78 years). 54.2% of all patients (n = 39) were male; 45.8% (n = 33) were female. In 30.6% (n = 22) a positive family history for the disease or a similar disease phenotype was reported. The median age at disease onset was 30 years (range 0-74 years). In 41.7% (n = 30) either the muscle or the neuromuscular junction was the predominant lesion site; 40.3% (n = 29) exhibited a more complex phenotype involving anterior horn cells or motor neurons, and 18.1% (n = 13) displayed a peripheral nerve disorder.
Molecular diagnoses
The initial diagnostic yield according to the laboratory reports was 30.6% (n = 22/72 patients). In addition, for 11 patients (15.3% of the cohort), 12 VUS in 11 different genes were reported to be potentially associated with the phenotype. After genotype-guided diagnostic reassessment and additional investigations, the final diagnostic yield was increased to 37.5% (n = 27/72 patients). In 39 individuals (54.2%) no relevant variants were identified. The main characteristics of patients with the reported variants are summarized in Table 1 .
Eighteen of 27 patients (66.7%) with a genetic diagnosis after reassessment had an autosomal recessive disorder and eight (29.6%) an autosomal dominant disorder. In one patient (3.7%) a dual pathology involving DMD (hemizygous two exon deletion) and SCN4A (heterozygous missense variant) was diagnosed.
Overall, a total of 24 different OMIM (Online Mendelian Inheritance in Man) diagnoses could be established. SPG7 (MIM#607259) was represented three times and SPG4 (MIM#182601) and CMS4C (MIM#608931) were each represented twice in this cohort. Each of the remaining 21 diagnoses was represented once.
Genotype-guided diagnostic reassessment and variant reclassification
After diagnostic reassessment, the results of unknown clinical significance were reconsidered to be (probably) disease-related in five of 11 patients ( Fig. 1 , Table S2 ). In three of these five patients, this was due to specific phenotype features revealed in a second diagnostic step, e.g. muscle histology (ACMG criterion PP4), segregation analysis (ACMG criteria PM3 + PP1) and biochemical (functional) confirmation of pathogenicity (ACMG criterion PS3). One VUS in DNM2 was not considered disease-related due to the carriership of an unaffected parent, and another patient carrying a VUS in SMCHD1 showed normal D4Z4 methylation (no diagnosis). In the remaining four patients with reported VUS, pathogenicity remained uncertain after diagnostic reassessment (possible diagnosis).
As an example, a VUS in BICD2 (patient 17) led to an extensive review of the literature by the treating clinicians. Although family genotyping could not be done, previously reported families with missense variants in BICD2 were strikingly reminiscent of the patient's specific clinical presentation (lower motor neuron disease, areflexia and marked predominance of lower limbs), and so the variant was upgraded to 'likely pathogenic' (likely diagnosis). Similarly, a VUS in TRPV4 (affecting a functional protein domain) was also upgraded to 'likely pathogenic' due to a highly specific phenotypic fit in patient 38 (lower motor neuron disease, vocal cord palsy and early respiratory involvement). One VUS in the RYR1 gene (which coexisted with one likely pathogenic variant in the same gene) in patient 39 could be changed to 'likely pathogenic' based on the specific features of a secondarily performed muscle biopsy, supporting RYR1-related myopathy. Patient 50 with spastic paraparesis carried one VUS (along with one pathogenic variant) in KIF1A. After ES, these variants were shown to segregate with the phenotype in two affected out of four siblings, leading to the (likely) diagnosis of SPG30. A heterozygous carriership was confirmed in both unaffected parents. Another patient with spastic paraparesis (patient 56) had one VUS in CYP7B1 (along with a pathogenic variant). A biochemical analysis of serum 27-hydroxycholesterol levels led to an upgrade to 'likely pathogenic', confirming SPG5A. been diagnosed with either gene panel due to atypical disease manifestations which would have led to the selection of a wrong panel. Patient 11 carrying a mutation in the polyneuropathy gene MFN2 could only be diagnosed with ES because of spastic paraparesis being the leading phenotype. Another patient (patient 59) with a predominant polyneuropathy phenotype and action-induced myoclonus was eventually diagnosed with progressive myoclonic epilepsy due to biallelic pathogenic variants in SCARB2 ( Table 2) .
Actionable variants
In our cohort of 72 individuals, an actionable variant was reported in one male patient aged 52 years (1.4%). The mutation in BRCA2 (NM_000059.3: c.5073dup) was considered pathogenic according to ClinVar, (https://www.ncbi.nlm.nih.gov/clinvar).
Discussion
Several studies have stressed the importance of a critical reconsideration of initial genetic laboratory results from a clinical perspective [19, 20] . Diagnostic reassessment approaches after NGS testing are increasingly entering medical practice, since ACMG recommends not using VUS for clinical decision-making [16] . In our study, data are provided that argue in favour of such an approach. The diagnostic yield of ES in our cohort of 72 patients with NMDs was 30.6% based on the initial laboratory reports. This number could be increased to 37.5% after genotype-guided diagnostic reassessment and conducting further investigations. Evidence that led to an upgrading of VUS was either derived from additional histological, biochemical or segregation analysis or by reassessing phenotypes in comparison with families from the literature. This was the case for two of our patients (with variants in BICD2 and TRPV4), whose phenotypic overlap with previously reported patients was so specific that the reported VUS were eventually considered likely pathogenic. As exemplified by these two patients, genotype-guided secondary phenotyping makes sense, as it might reveal highly specific but initially overlooked clinical features. However, one has to be aware that this approach harbours the danger of a biased reassessment, especially if done by the treating clinician alone. Any decisions regarding variant reclassification should therefore be discussed by a multidisciplinary team to minimize this risk.
Our study also adds data for the discussion whether a targeted or an exome-based NGS approach is most appropriate for routine diagnostics. Whilst comprehensive gene panels seem to offer yields similar to ES, it is questionable how well narrow gene panels perform in clinical practice (some health insurance companies, e.g. in Germany, set a limit of 25 kb) [5] . This point is particularly relevant for ambiguous phenotypes as often observed in NMDs, easily leading to a wrong panel selection.
In our cohort, a considerable proportion of patients exhibited such complex phenotypes with overlapping symptoms between various neuromuscular disease subgroups (and thus panels). For instance, in patient 11, the clinically leading feature was spastic paraparesis. ES revealed a pathogenic variant in the 'polyneuropathy gene' MFN2, a gene which has been associated with an additional spasticity in rare cases [24] . The usually prominent polyneuropathy phenotype was clinically not noticeable and only in retrospect evident in nerve conduction studies. Another patient (patient 59) clinically presented with a demyelinating polyneuropathy and action-induced myoclonus. ES was performed due to the complex, syndromic phenotype and surprisingly revealed a clearly pathogenic homozygous mutation in SCARB2, a gene that is usually associated with progressive myoclonic epilepsy. Subsequently, the condition could be stabilized by antiepileptic treatment with levetiracetam. The association between SCARB2 and a polyneuropathy phenotype is rare but has already been described as part of the clinical spectrum [25] .
Our analysis demonstrated that appropriately chosen simulated gene panels <25 kb would have covered only 59.3% of the responsible disease genes detected by ES. More comprehensive panels expectedly achieved a higher diagnostic yield, covering 92.6% of the detected genes. However, the two aforementioned cases resolved by ES would have been missed even by the comprehensive gene panel.
In conclusion, our analysis supports a systematic genotype-guided diagnostic reassessment after NGS in a multidisciplinary setting involving referring clinicians and geneticists. Our data further argue against the use of narrowly targeted gene panels in NMDs due to ambiguously overlapping phenotypes.
